IS ADDING RIBOCICLIB TO FULVESTRANT COST-EFFECTIVE IN TREATING POST-MENOPAUSAL WOMEN WITH HR+/ HER2-ADVANCED BREAST CANCER - A US PAYER PERSPECTIVE COST-UTILITY ANALYSIS Conference Paper
- Overview
- Additional Document Info
- View All
Overview
published proceedings
- VALUE IN HEALTH
author list (cited authors)
- Berrios, K., Burum, A., Jeong, E., & Zhong, L.
complete list of authors
- Berrios, K||Burum, A||Jeong, E||Zhong, L
publication date
- January 2022
published in
- Value in Health Journal